| Name | Title | Contact Details |
|---|---|---|
Travis Nevels |
Director, ASCVD Marketing Strategy | Profile |
Mike Driscoll |
Regional Sales Director | Profile |
Grant Jackson |
Director, Renal Marketing Strategy | Profile |
Timothy Moody |
Associate Director, Supply Chain Planning | Profile |
Maria Rocca-Ichikawa |
Head Finance Global Drug | Profile |
Headquartered in New York City, Acreage is a multi-state operator of cannabis cultivation and retailing facilities in the U.S., including the company`s national retail store brand, The Botanist. Acreage`s wide range of national and regionally available cannabis products include the award-winning Botanist brand, the highly recognizable Tweed brand, the Prime medical brand in Pennsylvania, the Innocent edibles brand in Illinois and others. Acreage also owns Universal Hemp, LLC, a hemp subsidiary dedicated to the distribution, marketing and sale of CBD products throughout the U.S. Since its founding in 2011, Acreage has focused on building and scaling operations to create a seamless, consumer-focused, branded experience.
TransparentRx is a fiduciary and transparent PBM company that specializes in providing effective solutions for self-funded employer groups, health plans, TPAs, business coalitions and government entities.
Axcan Pharma Inc is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Direct Success is a Wall Township, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Oncopeptides is a pharmaceutical company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The company is focusing on the development of the lead product candidate melflufen, a first-in-class anti-cancer peptide-drug conjugate that rapidly delivers an alkylating payload into tumor cells. Melflufen is in development as a new treatment for the hematological cancer multiple myeloma and is currently being evaluated in multiple clinical studies including the pivotal phase 2 HORIZON study and the ongoing phase 3 OCEAN study. Oncopeptides` headquarters is in Stockholm, Sweden with U.S. headquarters in Boston, Mass. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the ticker ONCO.